In this study, we comprehensively profiled 702 proteins in serum samples from stage III melanoma patients (n = 39) treated with neoadjuvant anti-PD-1 and anti-CTLA-4 therapy to identify circulating ICI biomarkers. Here, CTLA4 is linked to melanoma.